智能配用电
Search documents
科大智能科技股份有限公司(H0334) - 申请版本(第一次呈交)
2026-01-18 16:00
香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責,對其準確性或完整 性亦不發表任何意見,並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 CSG Smart Science & Technology Co., Ltd. 科大智能科技股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司(「聯交所」)與證券及期貨事務監察委員會(「證監 會」)的要求而刊發,僅用作提供資訊予香港公眾人士。 本申請版本為草擬本,其所載資料並不完整,亦可能會作出重大變動。 閣下閱覽本文件,即代 表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或承銷團成員表示同意: 倘於適當時候向香港公眾人士提出要約或邀請,有意投資者務請僅據呈交香港公司註冊處處長 註冊的本公司招股章程作出投資決定,有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料,概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定; (b) 在聯交所網站登載本文件或其補充 ...
三星医疗:公司主营业务为智能配用电及医疗服务两大板块
Zheng Quan Ri Bao Wang· 2025-12-23 13:52
证券日报网讯12月23日,三星医疗(601567)在互动平台回答投资者提问时表示,公司主营业务为智能 配用电及医疗服务两大板块,未涉及可控核聚变领域。 ...
三星医疗:主营业务为智能配用电及医疗服务两大板块,未涉及可控核聚变领域
Mei Ri Jing Ji Xin Wen· 2025-12-23 12:10
(文章来源:每日经济新闻) 每经AI快讯,有投资者在投资者互动平台提问:贵司是否涉及可控核聚变领域? 三星医疗(601567.SH)12月23日在投资者互动平台表示,公司主营业务为智能配用电及医疗服务两大 板块,未涉及可控核聚变领域。 ...
三星医疗:未涉及可控核聚变领域
Sou Hu Cai Jing· 2025-12-23 11:10
Core Viewpoint - Samsung Medical confirmed that it does not engage in the field of controllable nuclear fusion, focusing instead on its main business areas of smart power distribution and medical services [1] Group 1 - Investors inquired about Samsung Medical's involvement in controllable nuclear fusion [1] - Samsung Medical's response clarified its primary business operations [1]
三星医疗(601567.SH):未涉及可控核聚变领域
Ge Long Hui· 2025-12-23 10:51
Group 1 - The core business of Samsung Medical (601567.SH) consists of two main segments: smart power distribution and medical services [1] - The company has clarified that it is not involved in the field of controllable nuclear fusion [1]
三星医疗(601567)季报点评:海外配电在手订单持续高增
Xin Lang Cai Jing· 2025-10-31 06:30
Core Viewpoint - Samsung Medical reported a decline in Q3 revenue and net profit, primarily due to slow domestic order deliveries and low-margin overseas orders, but expects recovery in gross margins and prices with upcoming tenders [1][2]. Financial Performance - Q3 revenue reached 3.108 billion yuan, down 9.56% year-on-year and 28.42% quarter-on-quarter; net profit attributable to shareholders was 298 million yuan, up 55.22% year-on-year and down 59.74% quarter-on-quarter [1]. - For the first three quarters of 2025, revenue was 11.08 billion yuan, up 6.19% year-on-year; net profit was 1.528 billion yuan, down 15.85% year-on-year, with a gross margin of 28.46%, down 7.74 percentage points [2]. Order Backlog and Market Expansion - As of Q3 2025, the total order backlog reached 17.914 billion yuan, up 14.69% year-on-year, with overseas distribution orders at 2.169 billion yuan, up 125.45% [2]. - The company is focusing on expanding its presence in Europe, the Middle East, and Latin America, achieving initial orders in several countries, including Hungary and Romania [2]. Business Development - The company maintains a leading position in domestic network business and is actively expanding its customer base outside the network, targeting large clients in the renewable energy sector and new market segments [3]. Profit Forecast and Valuation - The company has adjusted its net profit forecasts for 2025-2027 downwards by 16.23%, 15.21%, and 10.60% respectively, with expected net profits of 2.261 billion, 2.765 billion, and 3.491 billion yuan [4]. - The target price is set at 28.32 yuan, maintaining a "buy" rating based on adjusted earnings multiples [4].
三星医疗:目前没有军品业务
Ge Long Hui· 2025-09-04 08:41
Core Viewpoint - Samsung Medical (601567.SH) has developed an integrated solution in the field of smart energy management to meet the needs of domestic and international customers [1] Group 1 - The company has formed a comprehensive solution in smart power distribution, which includes smart meters, smart terminals, communication modules, system software, transformers, box-type substations, switch cabinets, power boxes, photovoltaic/wind power box transformers, charging piles, inverters, and energy storage-related products [1] - Currently, the company does not have any military-related business [1]
三星医疗(601567.SH):目前没有军品业务
Ge Long Hui· 2025-09-04 08:19
Core Viewpoint - Samsung Medical (601567.SH) has developed an integrated solution in the field of smart energy management to meet the needs of domestic and international customers, which includes various products and systems [1] Group 1 - The company has formed a comprehensive solution in smart power distribution, which encompasses smart meters, smart terminals, communication modules, system software, transformers, box-type substations, switch cabinets, power boxes, photovoltaic/wind power box transformers, charging piles, inverters, and energy storage-related products [1] - Currently, the company does not have any military-related business [1]
港股异动 | 威胜控股(03393)再涨超9% 绩后累涨逾25% 海外数据中心新订单表现强劲
Zhi Tong Cai Jing· 2025-08-29 03:37
Core Viewpoint - Weisheng Holdings (03393) has seen a significant stock price increase of over 25% following the release of its interim results, with a current trading price of 11.19 HKD and a trading volume of 47.63 million HKD [1] Financial Performance - The company reported a revenue of 4.39 billion RMB, representing a year-on-year increase of 17.34% [1] - Net profit attributable to shareholders reached 440 million RMB, marking a year-on-year increase of 32.81% [1] Market Analysis - CICC's report indicates that Weisheng Holdings' performance exceeded expectations, driven by expansion in external markets such as communications, and better-than-industry performance in domestic meter deliveries and collections [1] - Citigroup's report highlights that the net profit for the first half of the year rose by 32.8% to 440 million RMB, surpassing the market's expectation of a full-year profit increase of 28.3% to 906 million RMB [1] Business Segments - The revenue from the smart distribution and utilization system and solutions (ADO) segment grew by 9.2% year-on-year, primarily due to strong product demand from overseas data centers [1] - Management maintains a dividend payout ratio of 50% for 2025 and capital expenditure guidance, anticipating strong performance in new orders from overseas data centers, which is expected to support a 21% growth in ADO business revenue for the year [1]
东兴证券:给予海兴电力买入评级
Zheng Quan Zhi Xing· 2025-08-23 10:08
Core Viewpoint - The report highlights that Haixing Electric's performance in the first half of 2025 fell short of expectations due to increased counter-cyclical investments and industry cycle impacts, leading to a decline in both revenue and net profit [2][4]. Financial Summary - Haixing Electric reported a total revenue of 1.92 billion yuan for the first half of 2025, representing a year-on-year decrease of 14.7% [2]. - The net profit attributable to shareholders was 400 million yuan, down 25.7% year-on-year [2]. - The comprehensive gross margin for the first half of 2025 was 41.56%, a decrease of 2.64% compared to the same period last year [2]. - The period expense ratio increased to 17.58%, up 0.57% from the previous year [2]. Business Development - The company is actively participating in domestic and overseas markets, securing significant contracts such as 140 million yuan from the State Grid and 49.9 million yuan from Southern Power Grid [3]. - Haixing Electric is expanding its marketing channels in key countries and new markets, with the launch of the "Orca" platform and the commencement of operations at a smart ultrasonic water meter factory in South Africa [3]. - The company aims for multi-market and multi-category collaborative development while consolidating its domestic base and expanding overseas [3]. Competitive Advantage - Haixing Electric focuses on providing comprehensive solutions and localized strategies, enhancing its brand competitiveness [4]. - The company has achieved a revenue share of approximately 60% from system software and solutions in its overseas smart electricity business in 2024 [4]. - By leveraging product and service capabilities, Haixing Electric has established deep customer relationships and built a competitive brand advantage [4]. Profit Forecast and Investment Rating - The projected net profits for Haixing Electric from 2025 to 2027 are 1.023 billion yuan, 1.188 billion yuan, and 1.387 billion yuan, respectively, with corresponding EPS of 2.10, 2.44, and 2.85 yuan [4]. - The current stock price corresponds to PE ratios of 13, 11, and 10 times for 2025 to 2027 [4]. - The report maintains a "strong buy" rating for the company [4].